138 related articles for article (PubMed ID: 9468582)
1. Simultaneous measurement of circulating intercellular adhesion molecule-1 and serum copper zinc superoxide dismutase activity in patients with malignant melanoma.
Wollina U; Karte K; Olbertz K; Hipler UC
Oncol Rep; 1998; 5(2):473-6. PubMed ID: 9468582
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of serum levels of soluble intercellular adhesion molecule-1 and soluble L-selectin in malignant melanoma.
Yamada M; Yanaba K; Takehara K; Sato S
Arch Dermatol Res; 2005 Dec; 297(6):256-60. PubMed ID: 16222535
[TBL] [Abstract][Full Text] [Related]
3. The serum levels of soluble intercellular adhesion molecule-1 (sICAM-1) and soluble gp130 (sgp130) in different tumour stages. Correlation between the two parameters in progression of malignancy.
Kovacs E
Biomed Pharmacother; 2005 Oct; 59(9):498-500. PubMed ID: 16202558
[TBL] [Abstract][Full Text] [Related]
4. A distinct profile of serum levels of soluble intercellular adhesion molecule-1 and intercellular adhesion molecule-3 in mycosis fungoides and Sézary syndrome.
López-Lerma I; Estrach MT
J Am Acad Dermatol; 2009 Aug; 61(2):263-70. PubMed ID: 19615537
[TBL] [Abstract][Full Text] [Related]
5. Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma.
Boyano MD; Garcia-Vázquez MD; López-Michelena T; Gardeazabal J; Bilbao J; Cañavate ML; Galdeano AG; Izu R; Díaz-Ramón L; Raton JA; Díaz-Pérez JL
Br J Cancer; 2000 Oct; 83(7):847-52. PubMed ID: 10970683
[TBL] [Abstract][Full Text] [Related]
6. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.
Bosserhoff AK; Kaufmann M; Kaluza B; Bartke I; Zirngibl H; Hein R; Stolz W; Buettner R
Cancer Res; 1997 Aug; 57(15):3149-53. PubMed ID: 9242442
[TBL] [Abstract][Full Text] [Related]
7. Hemodialysis procedure does not affect the levels of sICAM-1 and sVCAM-1 in patients with end stage renal disease.
Liakopoulos V; Eleftheriadis T; Kyropoulos T; Voliotis G; Potamianos S; Zengos N; Stefanidis I; Heintz B
Ren Fail; 2005; 27(3):315-21. PubMed ID: 15957549
[TBL] [Abstract][Full Text] [Related]
8. Soluble intercellular adhesion molecule-1 as a prognostic marker for stage II colorectal cancer patients.
Toiyama Y; Miki C; Inoue Y; Okugawa Y; Koike Y; Yokoe T; Tanaka K; Kusunoki M
Ann Surg Oncol; 2008 Jun; 15(6):1617-24. PubMed ID: 18368454
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of serum VEGF in melanoma patients: a pilot study.
Ascierto PA; Leonardi E; Ottaiano A; Napolitano M; Scala S; Castello G
Anticancer Res; 2004; 24(6):4255-8. PubMed ID: 15736481
[TBL] [Abstract][Full Text] [Related]
10. The prognostic significance of serum levels of soluble intercellular adhesion molecules-1 in patients with primary extranodal non-Hodgkin lymphomas.
Lei KI; Johnson PJ
Cancer; 2000 Sep; 89(6):1387-95. PubMed ID: 11002235
[TBL] [Abstract][Full Text] [Related]
11. Levels of soluble intercellular adhesion molecule-1 and total sialic acid in serum of patients with colorectal cancer.
Basoglu M; Yildirgan MI; Taysi S; Yilmaz I; Kiziltunc A; Balik AA; Celebi F; Atamanalp SS
J Surg Oncol; 2003 Jul; 83(3):180-4. PubMed ID: 12827689
[TBL] [Abstract][Full Text] [Related]
12. High plasma proteasome levels are detected in patients with metastatic malignant melanoma.
Stoebner PE; Lavabre-Bertrand T; Henry L; Guiraud I; Carillo S; Dandurand M; Joujoux JM; Bureau JP; Meunier L
Br J Dermatol; 2005 May; 152(5):948-53. PubMed ID: 15888151
[TBL] [Abstract][Full Text] [Related]
13. Correlation between soluble intercellular adhesion molecule 1 level and extracellular superoxide dismutase activity in rheumatoid arthritis: a possible association with disease activity.
Ugur M; Yildirim K; Kiziltunc A; Erdal A; Karatay S; Senel K
Scand J Rheumatol; 2004; 33(4):239-43. PubMed ID: 15370719
[TBL] [Abstract][Full Text] [Related]
14. Results of the determination of serum markers in patients with malignant melanoma.
Lugović L; Situm M; Buljan M; Poduje S; Sebetić K
Coll Antropol; 2007 Jan; 31 Suppl 1():7-11. PubMed ID: 17469741
[TBL] [Abstract][Full Text] [Related]
15. [Serum levels of soluble intercellular molecule 1 (sICAM-1) in endometriosis].
Leng J; Lang J; Zhao D; Liu D
Zhonghua Yi Xue Za Zhi; 2002 Feb; 82(3):189-90. PubMed ID: 11953158
[TBL] [Abstract][Full Text] [Related]
16. A case of malignant melanoma: disease progression correlated with serum levels of 5-S-Cysteinyldopa (5-S-CD) and intercellular adhesion molecule-1 (ICAM-1).
Ye Z; Kageshita T; Ishihara T; Ito S; Ono T
J Dermatol; 1995 May; 22(5):370-5. PubMed ID: 7673560
[TBL] [Abstract][Full Text] [Related]
17. [Relation of the soluble cytoadhesion molecules VCAM-1 and ICAM-1 to selected clinical and laboratory indicators in multiple myeloma].
Scudla V; Budíková M; Bacovský J; Ordeltová M; Opíchalová D; Heincová V
Vnitr Lek; 1999 Oct; 45(10):583-90. PubMed ID: 10951865
[TBL] [Abstract][Full Text] [Related]
18. Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma.
Abraha HD; Fuller LC; Du Vivier AW; Higgins EM; Sherwood RA
Br J Dermatol; 1997 Sep; 137(3):381-5. PubMed ID: 9349333
[TBL] [Abstract][Full Text] [Related]
19. MIA, a novel serum marker for progression of malignant melanoma.
Bosserhoff AK; Lederer M; Kaufmann M; Hein R; Stolz W; Apfel R; Bogdahn U; Buettner R
Anticancer Res; 1999; 19(4A):2691-3. PubMed ID: 10470221
[TBL] [Abstract][Full Text] [Related]
20. Circulating vascular endothelial growth factor in cutaneous malignant melanoma.
Pelletier F; Bermont L; Puzenat E; Blanc D; Cairey-Remonnay S; Mougin C; Laurent R; Humbert P; Aubin F
Br J Dermatol; 2005 Apr; 152(4):685-9. PubMed ID: 15840099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
